ExpreS2ion Biotech Holding AB (EXPRS2) Fair Value & Analysis

Healthcare · SE · Market cap 14.2M SEK

Below-average quality, trading 55% below our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case (kr 1.88). The market is more pessimistic than our downside scenario.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (kr 1.88 to kr 3.55) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range kr 1.26 – kr 1,819 · fair‑value band kr 1.88 – kr 3.55 · the kr 1.28 price screens below the kr 2.84 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

ExpreS2ion Biotech Holding AB (EXPRS2) currently trades at kr 1.28, while our model-based Fair Value estimate is kr 2.84, implying the stock looks roughly 121.9% undervalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Trailing-twelve-month revenue stands at 10.9M SEK. Revenue grew 132.3% year over year. It earns a return on equity of -88.0%. The balance sheet holds a net cash position of 45.3M SEK. Fundamentals as of Aug 13, 2026

Our scenario range runs from kr 1.88 (bear case) to kr 3.55 (bull case); at kr 1.28, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -60% fair-value upside, at 122%, EXPRS2 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2.

Full company description

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a human clinical Phase III-validated technology platform for the development and production of the active material in vaccines under the GlycoX-S2. Further, it out licenses its ExpreS2 platform to research institutes and pharmaceutical companies; and sells ExpreS2 test kits and reagents for research purposes or diagnostic applications. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

ExpreS2ion Biotech Holding AB reported revenue of kr 3.7M in FY2025 versus kr 12.2M in FY2021, a compound −26.1%/yr. Reported net income was −kr 38.1M in FY2025.

Watch EXPRS2: get an alert when its fair value changes →

Peer Group

Biotechnology · 630 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Insider activity: 30/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.